Lamotrigine in clinical practice: Long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center

Epilepsy and Behavior

Volumn 12, Issue 2, 2008, Pages 262-268

  Bootsma, H P R ^a   Vos, A M ^b   Hulsman, J ^a   Lambrechts, D ^a   Leenen, L ^a   Majoie, M ^a   Savelkoul, M ^a   Schellekens, A ^a   Aldenkamp, A P ^a,c  

^a EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Lamotrigine; Long term retention; Plasma levels; Side effects of antiepileptic drugs

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; AGGRESSION; AGITATION; ALERTNESS; ANTICONVULSANT THERAPY; APATHY; ARTICLE; ASTHENIA; ATAXIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL PRACTICE; COGNITION; COMBINATION CHEMOTHERAPY; CONFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EAR DISEASE; ENDOCRINE DISEASE; EXHAUSTION; EYE DISEASE; FATIGUE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; HUMAN; INSOMNIA; IRRITABILITY; LARYNX DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MONOTHERAPY; MOOD DISORDER; NOSE DISEASE; PATIENT REFERRAL; PERSONAL EXPERIENCE; RECOMMENDED DRUG DOSE; RHEUMATIC DISEASE; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; SOMNOLENCE; TERTIARY HEALTH CARE; TREMOR; VISUAL DISORDER;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSY; FOLLOW-UP STUDIES; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; PATIENT DROPOUTS; PATIENT SATISFACTION; SEIZURES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TRIAZINES;

EID: 37749042049     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.10.004     Document Type: Article

References (28)

1. Shorvon S.D., Fish D.R., Perucca E., and Dodson W.E. The treatment of epilepsy. 2nd ed. (2004), Blackwell Science, London
2. Bootsma H.P., Coolen F., Aldenkamp A.P., et al. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 5 (2004) 380-387
3. Bootsma H.P., Ricker L., Diepman L., et al. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 10 (2007) 296-303
4. Sander J.W. New antiepileptic drugs in practice: how do they perform in the real world?. Acta Neurol Scand 112 (2005) 26-29
5. Mohanraj R., and Brodie M.J. Measuring the efficacy of antiepileptic drugs. Seizure 12 (2003) 413-443
6. Zacarra G., Messori A., Cincotta M., et al. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?. Acta Neurol Scand 114 (2006) 157-168
7. Chadwick D. Better comparisons of antiepileptic drugs: what measures of efficacy?. Pharm World Sci 19 (1997) 214-216
8. Bartoli A., Guerrini R., Belmonte A., Alessandri M.G., Gatti G., and Perucca E. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 19 (1997) 252-260
9. Luckasson R., Coulter D.L., and Polloway E.A. Mental retardation: definition, classification, and systems of supports (1992), Am. Assoc. on Ment. Retard, Washington, DC
10. Binnie C.D., Debets R.M., Engelsman M., et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 4 (1989) 222-229
11. Brodie M.J. Lamotrigine. Lancet 339 (1992) 1397-1400
12. Jawad S., Richens A., Goodwin G., and Yuen W.C. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 30 (1989) 356-363
13. Loiseau P., Yuen A.W., Duche B., Menager T., and Arne-Bes M.C. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 7 (1990) 136-145
14. Matsuo F., Bergen D., Faught E., et al. for the U.S. Lamotrigine Protocol 05 Clinical Trial Group. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 43 (1993) 2284-2291
15. Messenheimer J., Ramsay R.E., Willmore L.J., et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 35 (1994) 113-121
16. Schapel G.J., Beran R.G., Vajda F.J., et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 56 (1993) 448-453
17. Hirsch L.J., Weintraub D., Du Y., et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 63 (2004) 1022-1026
18. Morris R.G., Lee M.Y., Cleanthous X., and Black A.B. Long-term follow-up using a higher target range for lamotrigine monitoring. Ther Drug Monit 26 (2004) 626-632
19. Morris R.G., Black A.B., Harris A.L., Batty A.B., and Sallustio B.C. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 46 (1998) 547-551
20. Neels H.M., Sierens A.C., Naelaerts K., Scharpe S.L., Hatfield G.M., and Lambert W.E. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 42 (2004) 1228-1255
21. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants?. Clin Pharmacokinet 38 (2000) 191-204
22. Froscher W., Keller F., Vogt H., and Kramer G. Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels. Epileptic Disord 4 (2002) 49-56
23. Deckers C.L., Hekster Y.A., Keyser A., Meinardi H., and Renier W.O. Drug load in clinical trials: a neglected factor. Clin Pharmacol Ther 62 (1997) 592-595
24. Collins T.L., Petroff O.A., and Mattson R.H. A comparison of four new antiepileptic medications. Seizure 9 (2000) 291-293
25. Lhatoo S.D., Wong I.C., Polizzi G., and Sander J.W. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41 (2000) 1592-1596
26. Wong I.C., Chadwick D.W., Fenwick P.B., Mawer G.E., and Sander J.W. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Epilepsia 40 (1999) 1439-1445
27. Wong I.C., Mawer G.E., Sander J.W., and Lhatoo S.D. A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia 42 (2001) 1354-1358
28. Faught E., Matsuo F.E., Schachter S., Messenheimer J., and Woble G.P. Long-term tolerability of lamotrigine; data from a 6-year continuation study. Epilepsy Behavior 5 (2004) 31-36